Conference
Abstract P1-12-10: Safety and efficacy of trastuzumab emtansine (T-DM1) in 399 patients with central nervous system metastases: Exploratory subgroup analysis from the KAMILLA study
Abstract
Abstract
Introduction T-DM1 treatment significantly improved overall survival and had a lower incidence of grade ≥3 adverse events (AEs) vs capecitabine plus lapatinib in patients (pts) with HER2-positive advanced breast cancer (BC) in the EMILIA study, including pts with treated, asymptomatic CNS metastases (mets). KAMILLA is an ongoing, single-arm, open-label, phase 3b global safety study of T-DM1 in pts with HER2-positive …
Authors
Montemurro F; Ellis P; Delaloge S; Wuerstlein R; Anton A; Button P; Lindegger N; Barrios C
Volume
77
Publisher
American Association for Cancer Research (AACR)
Publication Date
February 15, 2017
DOI
10.1158/1538-7445.sabcs16-p1-12-10
Conference proceedings
Cancer Research
Issue
4_Supplement
ISSN
0008-5472